1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Therapy Analysis & Statistics in European Union, October 2019

Therapy Analysis & Statistics in European Union, October 2019

1-30 of about 200 reports

Menveo

Menveo

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewMenveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the ...

  • Industries : Therapy, Pathology
  • Countries : United States, European Union
Nimenrix

Nimenrix

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewNimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease ...

  • Industries : Therapy, Pathology
  • Countries : European Union, Europe
MenQuadfi

MenQuadfi

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewSanofi’s MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection. ...

  • Industries : Therapy
  • Countries : European Union, United States
Bexsero

Bexsero

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewBexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal ...

  • Industries : Therapy, Pathology, Medical Biotechnology, Pharmaceutical
  • Countries : United States, European Union
MenABCW-135Y

MenABCW-135Y

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewGlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials ...

  • Industries : Pathology, Therapy
  • Countries : United States, European Union
Delstrigo

Delstrigo

  • $ 10000
  • Industry report
  • July 2019

Delstrigo ([doravirine + lamivudine + tenofovir disoproxil fumarate (TDF)]; Merck and Co) is a single-tablet regimen being developed for the treatment of HIV-1 infection. The drug is a co-formulation of ...

  • Industries : Therapy
  • Countries : United States, European Union
Descovy

Descovy

  • $ 10000
  • Industry report
  • July 2019

Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) is a fixed-dose combination of two of Gilead’s nucleos(t)ide reverse transcriptase inhibitors, Emtriva (emtricitabine) and ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Ocaliva

Ocaliva

  • $ 10000
  • Industry report
  • July 2019

Ocaliva (obeticholic acid; Intercept Pharmaceuticals) is a selective farnesoid X receptor (FXR) agonist. FXR is a nuclear bile acid receptor involved in the regulation of bile acids, lipids, and possibly ...

  • Industries : Therapy
  • Countries : United States, European Union
Juluca

Juluca

  • $ 10000
  • Industry report
  • June 2019

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Industries : Therapy
  • Countries : United States, European Union
Prezista franchise

Prezista franchise

  • $ 10000
  • Industry report
  • June 2019

The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson and Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded ...

  • Industries : Therapy
  • Countries : United States, European Union
cabotegravir/rilpivirine

cabotegravir/rilpivirine

  • $ 10000
  • Industry report
  • June 2019

Cabotegravir is an integrase strand transfer inhibitor analog of Tivicay (dolutegravir; ViiV Healthcare), and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), branded as Edurant ...

  • Industries : Therapy
  • Countries : United States, European Union
Biktarvy

Biktarvy

  • $ 10000
  • Industry report
  • June 2019

Biktarvy ([bictegravir + emtricitabine + tenofovir alafenamide (TAF)]; Gilead) is an single-tablet regimen (STR) approved for the treatment of HIV-1 infection. It is a co-formulation of Gilead’s novel ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Complera

Complera

  • $ 10000
  • Industry report
  • June 2019

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Symtuza

Symtuza

  • $ 10000
  • Industry report
  • June 2019

Symtuza ([darunavir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)]; Johnson and Johnson) is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista, the ...

  • Industries : Therapy
  • Countries : United States, European Union
Atripla

Atripla

  • $ 10000
  • Industry report
  • June 2019

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Genvoya

Genvoya

  • $ 10000
  • Industry report
  • June 2019

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Stribild

Stribild

  • $ 10000
  • Industry report
  • June 2019

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Tivicay

Tivicay

  • $ 10000
  • Industry report
  • June 2019

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Isentress

Isentress

  • $ 10000
  • Industry report
  • June 2019

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Truvada

Truvada

  • $ 10000
  • Industry report
  • June 2019

Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Triumeq

Triumeq

  • $ 10000
  • Industry report
  • June 2019

Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ...

  • Industries : Therapy
  • Countries : United States, European Union
Dovato

Dovato

  • $ 10000
  • Industry report
  • June 2019

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • Industries : Therapy
  • Countries : United States, European Union
Odefsey

Odefsey

  • $ 10000
  • Industry report
  • June 2019

Odefsey ([rilpivirine + emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Johnson and Johnson) is a single-tablet regimen approved in the US and five major EU markets (France, Germany, Italy, Spain, ...

  • Industries : Therapy
  • Countries : United States, European Union
Reyataz

Reyataz

  • $ 10000
  • Industry report
  • June 2019

The Reyataz franchise comprises the standalone azapeptide protease inhibitor (PI) Reyataz (atazanavir; Bristol-Myers Squibb) and the fixed-dose combination of Reyataz and Tybost.

  • Industries : Therapy
  • Countries : United States, European Union
Lexapro

Lexapro

  • $ 10000
  • Industry report
  • March 2019

Lexapro (escitalopram; Allergan/Lundbeck/Mitsubishi Tanabe/Mochida) is a selective serotonin reuptake inhibitor, and acts by blocking the re-uptake of serotonin.

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Market Spotlight: Duchenne Muscular Dystrophy (DMD), Pharma Intelligence

Market Spotlight: Duchenne Muscular Dystrophy (DMD), Pharma Intelligence

  • $ 1318
  • Industry report
  • February 2019

This Market Spotlight report covers the Duchenne Muscular Dystrophy market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease ...

  • Industries : Therapy
  • Countries : European Union
Finerenone

Finerenone

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewFinerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of the ...

  • Industries : Therapy, Chronic Disease, Pathology
  • Countries : United States, Japan, European Union, Europe
Invokana

Invokana

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewInvokana (canagliflozin; Johnson and Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target ...

  • Industries : Therapy, Chronic Disease
  • Countries : United States, Japan, European Union
Arzerra

Arzerra

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewArzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane. ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Europe, Japan, European Union
Calquence

Calquence

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewCalquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Inhibition ...

  • Industries : Therapy, Medical Biotechnology, Oncology
  • Countries : United States, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on